ERBB2 and ovarian carcinoma: We have previously shown that lapatinib, an EGFR/ErbB2 kinase inhibitor, inhibits invasion and alters the lysosomal distribution from predominantly peripheral to predominantly perinuclear in ErbB2-positive ovarian cancer cells14.